Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol Engineers An Oral TYK2 Inhibitor With Biologic-Like Efficacy That Rivals JAK Safety

Executive Summary

The company's first set of Phase II data for its oral, selective TYK2 inhibitor in psoriasis showed a consistent dose response as well as safety that could rival the related JAK inhibitor class. BMS-986165 already is in Phase III for psoriasis; it's in Phase II for lupus and Crohn's disease.


Related Content

Bristol’s Integration Strategy With Celgene Includes “Ring-Fencing” Oncology Teams
As Expected: Shareholders Back Bristol's $74bn Celgene Buy
Bristol Values Celgene's Hematology, Immunology Portfolio At $74bn, But Does It Price In Risk?
Amid PD-1 Uncertainty, Bristol Under Pressure For M&A Activity
10 Things For Pfizer's New CEO To Worry About
Pfizer Eyes First-To-Market Opportunity In Alopecia
Celgene Maintains Otezla Confidence, But Is Reconsidering IBD Indications
Lilly Prices Olumiant For JAK Battle, But Misses Approval For Higher Dose
Ilumya Becomes Sun's New Branded Specialty Drug Pillar
Deal Watch: Celgene The Latest To Buy Into Nimbus’ Computational Chemistry Approach


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts